Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · RUBICON RESEARCH LIMITED · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
RUBICON RESEARCH LIMITED
NSE: RUBICON · BSE: 544578
NSE: RUBICON · BSE: 544578
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
RUBICON RESEARCH LIMITED
StateQ1 FY27 filed
Last close · 27 Oct 2026₹1,490.00
Market cap₹24.6k cr
TTM P/E · P/B · EV/EBITDA84.0 · 19.12 · 53.4
RUBICON RESEARCH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 1,754 |
| EBITDA (ex other income) | 400 |
| margin % | 22.8 |
| Owners' profit | 247 |
| EPS, as reported (₹) | 15.52 |
| ROE % · ROCE % | 19.1 · 24.3 |
| Debt / equity (x) | 0.20 |
| Cash from operations | 205 |
| Capex | (229) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · RUBICON RESEARCH LIMITED · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 4 quarters
| ₹ crore | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue | 412 | 476 | 514 | 534 |
| Profit before tax | 72 | 91 | 99 | 110 |
| Net profit | 54 | 73 | 77 | 85 |
| EPS (₹) | 3.49 | 4.46 | 4.66 | 5.13 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 84.0 | 30.1 | 136 of 158 | 14% |
| P/B | 19.1 | 3.0 | 160 of 163 | 2% |
| ROCE | 21.5 | 10.8 | 30 of 183 | 84% |
| ROE | 19.1 | 9.8 | 20 of 166 | 89% |
| Debt / Equity | 0.2 | 0.2 | 96 of 166 | 42% |
| EBITDA margin | 25.2 | 17.5 | 52 of 165 | 69% |
| Market cap | 24642 | 810 | 25 of 181 | 87% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · RUBICON RESEARCH LIMITED · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 27 Oct 2026 · Board meeting set for November 5 to approve September results | results | low | — | — |
| 9 Oct 2026 · US FDA inspection of Satara facility ends with 1 procedural observation | regulatory legal | high | — | — |
| 9 Oct 2026 · Quarterly dematerialisation compliance certificate filed | compliance | minimal | — | — |
| 8 Oct 2026 · ESOP allotment of 7,200 shares under 2022 stock option scheme | capital market events | low | — | — |
| 28 Sept 2026 · Rubicon Research closes trading window ahead of Q2 FY26 results | compliance | minimal | — | — |
| 29 Aug 2026 · Promoter General Atlantic sells 8.45% stake in Rubicon Research via open market | ownership changes | high | — | — |
| 27 Aug 2026 · General Atlantic sells 8.45% stake in Rubicon Research via open market | ownership changes | high | — | — |
| 26 Aug 2026 · 27th AGM: All 9 resolutions passed including dividend, ESOP 2026 and subsidiary merger | board shareholder meetings | low | — | — |
| 26 Aug 2026 · 27th AGM held; 9 resolutions tabled including dividend, ESOP 2026 and KIA merger | board shareholder meetings | low | — | — |
| 19 Aug 2026 · Rubicon Research Q1 FY27 transcript: PAT up 96%, EBITDA guidance raised to 23% | investor communications | medium | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in